Kaken Pharmaceutical
Sep 09, 2019
FDA approves Ofev for interstitial lung disease
Recently, the US FDA has approved a new drug therapy to treat adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. Ofev (nintedanib) capsules, the drug developed by Boehringer Ingelheim Pharmaceuticals, has shown efficacy in slowing down the rate of decline in pul...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
